HIV vaccine

HIV vaccine refers to a vaccine which would either protect individuals who do not have HIV from contracting the virus or otherwise serve as a therapeutic measure for those who have already been diagnosed with HIV. Despite extensive research and clinical trials, as of 2023, there is no fully effective HIV vaccine. However, various research efforts continue to explore potential vaccines due to the global impact of the Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS).

Background

HIV is a virus that attacks the body's immune system, specifically the CD4 cells (T cells), which help the immune system fight off infections. Untreated, HIV reduces the number of CD4 cells in the body, making the person more likely to get infections or infection-related cancers. Over time, HIV can destroy so many of these cells that the body can't fight off infections and disease, leading to AIDS, the last stage of HIV infection.

Vaccine Development Challenges

The development of an HIV vaccine faces several unique challenges. The high mutation rate of HIV means the virus can quickly change and evade the immune system. Additionally, the virus integrates into the host's genome, making it difficult for the immune system to target. The lack of a clear understanding of the correlates of protection—biomarkers that could guide vaccine development—is another significant hurdle.

Types of HIV Vaccines

Preventive Vaccines

Preventive HIV vaccines aim to prevent HIV infection in HIV-negative individuals. These vaccines are designed to elicit an immune response that is strong enough to either prevent HIV from establishing infection or control the virus without progressing to AIDS. Most preventive vaccines are in experimental stages, with various approaches being tested, including live attenuated vaccines, vector-based vaccines, and DNA-based vaccines.

Therapeutic Vaccines

Therapeutic HIV vaccines are intended to treat HIV-positive individuals. The goal of these vaccines is not to cure HIV but to strengthen the immune response to the virus in people who are already infected. This could potentially allow them to maintain a lower viral load and healthier immune system without continuous antiretroviral therapy (ART).

Clinical Trials

Several HIV vaccine candidates have reached clinical trials, with varying degrees of success. The RV144 trial in Thailand was the first to show some efficacy, reducing the risk of infection by approximately 31%. However, this level of efficacy is not high enough for widespread use, and further research is needed to improve the vaccine's effectiveness.

Future Directions

Research into HIV vaccines continues to explore new technologies and approaches, such as broadly neutralizing antibodies, mosaic antigens, and novel adjuvants. Scientists are also investigating the potential of using CRISPR gene-editing technology to create more effective vaccines.

Conclusion

The development of an effective HIV vaccine remains one of the most challenging and urgent goals in public health. Despite the hurdles, ongoing research and clinical trials provide hope that a vaccine will eventually be available to prevent HIV infection or to treat those already living with the virus.

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian